死亡受体3:一个矛盾的生物标志物和治疗点在泛癌症
Wenxuan Fang1, Junfang Du2, Zedong Xu3
1Guangxi Engineering Research Center for High-Value Utilization of Guangxi-Produced Authentic medicinal Herbs, Institute of Traditional Chinese and Zhuang-Yao Ethnic Medicine, Guangxi University of Chinese Medicine, Nanning 530200, China; Guangxi key laboratory of marine drugs, Institute of marine drugs, Guangxi University of Chinese Medicine, Nanning 530200, China.
死亡受体3 (DR3) 在癌症中起着双重作用,影响细胞亡和转移. 它的表达因癌症类型而异,并影响免疫细胞透和预后,突出其作为治疗点的潜力.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 死亡受体3 (DR3/TNFRSF25) 是瘤死因子受体超级家族的一部分.
- 在瘤亡,转移和免疫调节中,DR3具有复杂的作用.
研究的目的:
- 为了研究各种癌症类型的DR3表达模式.
- 分析DR3表达,瘤微环境和患者预后之间的相关性.
- 阐明DR3在癌症进展和免疫反应中的机制性作用.
主要方法:
- 文献综述和DR3表达的泛癌分析.
- 与免疫细胞透 (CD8+ T细胞,NK细胞) 和瘤突变负担 (TMB) 的相关性分析.
- 研究DR3信号通路,包括TL1A结合和NF-κB相互作用.
主要成果:
- DR3表现出显著的瘤类型特异性表达,在膀泌尿腺癌 (BLCA) 中表达高,在上皮层癌 (ACC) 中表达低.
- DR3表达与免疫细胞透,TMB和预后结果相关,其影响取决于上下文.
- 机理学研究揭示了DR3通过TL1A和NF-κB在亡/亡中的作用,以及其调节血管生成和抗瘤免疫力.
结论:
- DR3是一种多功能分子,在瘤学中具有作为生物标志物和治疗点的潜力.
- 由于DR3的双重作用和受异型和DcR3影响的上下文依赖信号,因此需要个性化治疗策略.
- 考虑到瘤微环境的进一步研究和精确评估对于DR3的临床应用至关重要.
更多相关视频
08:35Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
Published on: January 4, 2012
08:27Detection of Human Leukocyte Antigen Biomarkers in Breast Cancer Utilizing Label-free Biosensor Technology
Published on: March 24, 2015
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Internal Receptors
Therapeutic Index
Autophagic Cell Death
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
Overview of Cell Death
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the...
